Indicated for the treatment of Non-Small Cell Lung Cancer (NSCLC): EGFR Mutation-Positive NSCLC: First-line treatment for patients with metastatic NSCLC whose tumors have non-resistant EGFR mutations (Exon 19 deletions or Exon 21 L858R substitution). Squamous NSCLC: For patients progressing after platinum-based chemotherapy.

Dosage and administration

Dosage: 1 tablet (40 mg) once daily. ⚠️ CRITICAL ABSORPTION WARNING (Food Interaction): Food significantly blocks the absorption of the drug into your blood. Taking it with food renders the therapy ineffective. 🚫 DO NOT: Take with food. ✅ EMPTY STOMACH RULE: Take the tablet at least 1 hour before a meal OR 3 hours after a meal. Tip: Establish a routine, e.g., take it immediately upon waking up, wait one hour, then have breakfast.

Severe hepatic (liver) or renal (kidney) impairment. Pregnancy and breastfeeding. Interstitial Lung Disease (ILD). Children and adolescents under 18. Severe intolerance to galactose.

Side effects are common but manageable with proactive care: Diarrhea: Very common. Patients should have anti-diarrheal medication (Loperamide) ready and start it at the first sign. Rash / Acne: Keep skin moisturized and use sunscreen. Often indicates the drug is effective. Stomatitis: Mouth sores. Paronychia: Nail bed infections.

100% original product

Active ingredient

Afatinib

Manufacturer

Natco

Dosage 40 mg

Dosage form Tablets

Tablets per pack 28

Afanat (Afatinib) 40 mg

Name: Afanat
Brand: Natco
SKU: PROD-73
Price: 8350 UAH
Availability: InStock

8350₴ ~~9669₴~~ -14%

Afanat 40 mg is an advanced targeted therapy drug. Active ingredient: Afatinib (40 mg).

Manufacturer: Natco Pharma (India). A generic version of the brand-name drug Giotrif / Gilotrif.

Why is Afatinib superior?

Unlike first-generation inhibitors (reversible binding), Afanat creates an irreversible bond with the cancer cell receptors. It blocks the entire ErbB family (EGFR, HER2, ErbB4), shutting down the signaling pathways that cancer cells use to grow and survive. This mechanism offers broader control over the tumor.

✅ Patient Outcome: Significant progression-free survival in patients with specific lung cancer mutations.

Indicated for the treatment of Non-Small Cell Lung Cancer (NSCLC):

EGFR Mutation-Positive NSCLC: First-line treatment for patients with metastatic NSCLC whose tumors have non-resistant EGFR mutations (Exon 19 deletions or Exon 21 L858R substitution).
Squamous NSCLC: For patients progressing after platinum-based chemotherapy.

Dosage: 1 tablet (40 mg) once daily.

⚠️ CRITICAL ABSORPTION WARNING (Food Interaction):

Food significantly blocks the absorption of the drug into your blood. Taking it with food renders the therapy ineffective.

🚫 DO NOT: Take with food.
✅ EMPTY STOMACH RULE: Take the tablet at least 1 hour before a meal OR 3 hours after a meal.
Tip: Establish a routine, e.g., take it immediately upon waking up, wait one hour, then have breakfast.

Severe hepatic (liver) or renal (kidney) impairment.
Pregnancy and breastfeeding.
Interstitial Lung Disease (ILD).
Children and adolescents under 18.
Severe intolerance to galactose.

Side effects are common but manageable with proactive care:

Diarrhea: Very common. Patients should have anti-diarrheal medication (Loperamide) ready and start it at the first sign.
Rash / Acne: Keep skin moisturized and use sunscreen. Often indicates the drug is effective.
Stomatitis: Mouth sores.
Paronychia: Nail bed infections.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 02.03.2026

Active ingredient

Afatinib

Manufacturer

Natco

Dosage 40 mg

Dosage form Tablets

Tablets per pack 28

100% original product

Delivery across Ukraine

Customer reviews

What Customers Say

No reviews yet

Your review can be the first!

Afanat (Afatinib) 40 mg

What Customers Say

No reviews yet

Contact us

Request a call